BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 28295527)

  • 1. Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma.
    Mauro FR; Galieni P; Tedeschi A; Laurenti L; Del Poeta G; Reda G; Motta M; Gozzetti A; Murru R; Caputo MD; Campanelli M; Frustaci AM; Innocenti I; Raponi S; Guarini A; Morabito F; Foà R; Gentile M
    Am J Hematol; 2017 Jun; 92(6):529-535. PubMed ID: 28295527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group.
    Drozd-Sokołowska J; Zaucha JM; Żółtak T; Jamroziak K; Grzybowska-Izydorczyk O; Witkowska M; Waszczuk-Gajda A; Kaźmierczak M; Szczepaniak A; Subocz E; Knopińska-Posłuszny W; Hołojda J; Kopińska A; Hus I; Rybka J; Wołowiec D; Kwiatkowski J; Hałaburda K; Smolewski P; Giebel S; Wiktor-Jędrzejczak W
    Hematol Oncol; 2019 Oct; 37(4):383-391. PubMed ID: 31026087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma.
    Parikh SA; Habermann TM; Chaffee KG; Call TG; Ding W; Leis JF; Macon WR; Schwager SM; Ristow KM; Porrata LF; Kay NE; Slager SL; Shanafelt TD
    Am J Hematol; 2015 Apr; 90(4):334-8. PubMed ID: 25581025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
    Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
    Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: a multi-institutional retrospective study.
    Castillo JJ; Bower M; Brühlmann J; Novak U; Furrer H; Tanaka PY; Besson C; Montoto S; Cwynarski K; Abramson JS; Dalia S; Bibas M; Connors JM; Furman M; Nguyen ML; Cooley TP; Beltran BE; Collins JA; Vose JM; Xicoy B; Ribera JM;
    Cancer; 2015 Feb; 121(3):423-31. PubMed ID: 25251326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration.
    Stephens DM; Boucher K; Kander E; Parikh SA; Parry EM; Shadman M; Pagel JM; Cooperrider J; Rhodes J; Mato A; Winter A; Hill B; Gaballa S; Danilov A; Phillips T; Brander DM; Smith SM; Davids M; Rogers K; Glenn MJ; Byrd JC
    Haematologica; 2021 Nov; 106(11):2845-2852. PubMed ID: 33054118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
    Tsimberidou AM; O'Brien S; Kantarjian HM; Koller C; Hagemeister FB; Fayad L; Lerner S; Bueso-Ramos CE; Keating MJ
    Cancer; 2006 Sep; 107(6):1294-302. PubMed ID: 16902984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Hodgkin variant Richter transformation in chronic lymphocytic leukaemia and small lymphocytic lymphoma in British Columbia.
    Zhu K; Jamroz A; Huang S; Villa D; Freeman CL; Scott DW; Slack G; Sehn LH; Connors JM; Toze CL; Savage KJ; Gerrie AS
    Br J Haematol; 2022 Aug; 198(4):684-692. PubMed ID: 35567407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard therapies versus novel therapies in Hodgkin lymphoma.
    Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
    Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials.
    Böll B; Görgen H; Fuchs M; Pluetschow A; Eich HT; Bargetzi MJ; Weidmann E; Junghanß C; Greil R; Scherpe A; Schmalz O; Eichenauer DA; von Tresckow B; Rothe A; Diehl V; Engert A; Borchmann P
    J Clin Oncol; 2013 Apr; 31(12):1522-9. PubMed ID: 23509310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk-adapted therapy with three or six cycles of doxorubicin/bleomycin/vinblastine/dacarbazine plus involved-field radiation therapy in Hodgkin lymphoma, based on prognosis at diagnosis and early response: results from the GATLA study.
    Pavlovsky S; Corrado C; Pavlovsky MA; Prates MV; Zoppegno L; Giunta M; Cerutti I; Palomino E; Pagani F; Lastiri F; Bar D; Bezares RF; Avila G
    Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):181-5. PubMed ID: 20511162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment results in advanced stage Hodgkin's lymphoma: a retrospective study.
    Jain H; Sengar M; Nair R; Menon H; Laskar S; Shet T; Gujral S; Sridhar E
    J Postgrad Med; 2015; 61(2):88-91. PubMed ID: 25766339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.
    Cerci JJ; Pracchia LF; Linardi CC; Pitella FA; Delbeke D; Izaki M; Trindade E; Soares J; Buccheri V; Meneghetti JC
    J Nucl Med; 2010 Sep; 51(9):1337-43. PubMed ID: 20720036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
    Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
    Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma.
    Torok JA; Wu Y; Prosnitz LR; Kim GJ; Beaven AW; Diehl LF; Kelsey CR
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):54-9. PubMed ID: 25863754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
    Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
    Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.